PCSK9 inhibitors in sepsis: a new potential indication? (Q51266701)

2 April 2018

editorial

0 references

title

PCSK9 inhibitors in sepsis: a new potential indication? (English)

1 reference

2 April 2018

1 reference

2

Maciej Banach

1 reference

2 April 2018

3

Amirhossein Sahebkar

1 reference

2 April 2018

Amir Abbas Momtazi

1

0 references

language of work or name

English

0 references

publication date

14 December 2016

1 reference

2 April 2018

Expert Opinion on Investigational Drugs

published in

1 reference

2 April 2018

volume

26

1 reference

2 April 2018

page(s)

137-139

1 reference

2 April 2018

issue

2

1 reference

2 April 2018

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

cites work

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

Neutralization and transfer of lipopolysaccharide by phospholipid transfer protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

Lipopolysaccharide Is Cleared from the Circulation by Hepatocytes via the Low Density Lipoprotein Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

The Central Role of Proprotein Convertase Subtilisin/Kexin Type 9 in Septic Pathogen Lipid Transport and Clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

Inflammation stimulates the expression of PCSK9

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

PCSK9 is a critical regulator of the innate immune response and septic shock outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543784.2017.1272570

10.1080/13543784.2017.1272570

21 January 2018

Identifiers

DOI

1 reference

2 April 2018

PubMed ID

27967260

1 reference

2 April 2018